Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified Lymphodepletion and Auto-HSCT for Severe SLE
NCT00076752Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2004
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, fludarabine, cyclophosphamide in systemic lupus erythematosus (SLE), sponsored by National Cancer Institute. Started Jan 2004; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00076752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076752.